Gdf2025 D2s13 Navigating Challenges In

The presentation provided an overview of common deficiencies observed in drug manufacturing process and the critical ... The presentation provided an overview of information requests (IRs) with a description of more easily correctable deficiencies and ... This presentation provided an overview of comparative clinical endpoint BE study and Irritation/sensitization/adhesion studies. This session provided a brief overview of the Request for Reconsideration (RFR) process at the Division level under Generic User ... This presentation covered the GDUFA III and its significant changes from GDUFA II. It highlighted the roles of Regulatory Business ... The Generic Drugs Forum's first of four Q&A discussion panels, bringing together the speakers from the first session of day one.

This presentation provided an overview of general quality considerations of Drug Product Labeled for Alternate Dosing ... This presentation covered discrepancies commonly observed on the form 356h with the ANDA submission. Deviations on the form ... This session provided the commonalities that exist between the Agency and other regulatory jurisdictions regarding inactive ... This presentation provided an overview of common BE deficiencies identified in ANDAs associated with solid oral ... This premier event brings together FDA subject matter experts from every aspect of the pre-ANDA and ANDA assessment ... These presentations provided agency updates on policies, guidances, and initiatives from FDA, Medicines & Healthcare Products ...

This session provided an overview of the Inactive Ingredient Database (IID) and describe how to leverage the IID and Safety ...